.@Cellosaurus your resource, https://t.co/Do6nnbbJxa, was just reported to be used in "PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic N…": https://t.co/cW4hO779yP (https://t.co/EVIJEUI4W1). We appreciate the author's support of reproducibility. #STMpubli
RT @nanudasmd: Some interesting preclinical data suggesting the ability of PAK4-NAMPT inhibitors to re-sensitize pancreatic NETs to everoli…
RT @nanudasmd: Some interesting preclinical data suggesting the ability of PAK4-NAMPT inhibitors to re-sensitize pancreatic NETs to everoli…
RT @nanudasmd: Some interesting preclinical data suggesting the ability of PAK4-NAMPT inhibitors to re-sensitize pancreatic NETs to everoli…
Some interesting preclinical data suggesting the ability of PAK4-NAMPT inhibitors to re-sensitize pancreatic NETs to everolimus...will be interesting to see how this strategy enters the clinical arena @MCT_AACR @CureNETs @CarcinoidNETs https://t.co/dq7l8
New article: PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus https://t.co/v7z3po4wJt #pancreaticcancer #oncology https://t.co/BKsI7t1V7G
RT @asfarsazmi: PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus https://t.co/lbjUc5Yyts
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus https://t.co/lbjUc5Yyts